Sold as Fovane, Urese, Exna, Aquatag. Every FDA application for this active ingredient: 3 branded and 1 generic.
As of Nov 15, 2026, FDA lists 4 applications for Benzthiazide (sold as Fovane, Urese, Exna and others), first approved Oct 14, 1960, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| PrP-targeting siRNA Safety & Mechanism StudyPrion Disease · Broad Institute of MIT and Harvard | Phase 1 | Recruiting | Mar 3, 2026 |
| Oct 14, 1960 | ExnaNDA 12489 · New formulation or manufacturer | Ah Robins Inc | 18 | Discontinued |
| Aug 17, 1965 | AquatagNDA 16001 · New formulation or manufacturer | Solvay | 0 | Discontinued |
| Nov 19, 1976 | BenzthiazideANDA 83206 | Pvt Form | 0 | Discontinued |
| — | Fovane, UreseNDA 12128 | Pfizer | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer